The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Mutant p53: an oncogenic transcription factor
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function
Weisz, L., Zalcenstein, A., Stambolsky, P., Cohen, Y., Goldfinger, N., Oren, M., & Rotter, V. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1145 · Cited by 129
Retractedp53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“Consequently, its activation is impaired in cells carrying mutant p53 proteins (Haupt et al., 1997; Kubbutat et al., 1997; Midgley and Lane, 1997; Bushmann et al., 2000; Strano and Blandino, 2003; Lain and Lane, 2005).”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“Consequently, its activation is impaired in cells carrying mutant p53 proteins (Haupt et al., 1997; Kubbutat et al., 1997; Midgley and Lane, 1997; Bushmann et al., 2000; Strano and Blandino, 2003; Lain and Lane, 2005).”
BackgroundLive or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
Mutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Signer, S. H., Davidson, N., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,733
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 2×
“Structural studies have allowed to classify p53 mutant proteins in two large categories (Cho et al., 1994; Bullock and Fersht, 2001; Joerger et al., 2005): (a) DNA contactdefective mutants (His273, Trp248), which include those mutants whose mutation impacts on the residues composing the DNA/protein…”
BackgroundT antigen is bound to a host protein in SY40-transformed cells
LANE, D. P., & CRAWFORD, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,394
p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development
Yang, A., Schweitzer, R., Sun, D., Kaghad, M., Walker, N., Bronson, R. T., Tabin, C., Sharpe, A., Caput, D., Crum, C., et al. (1999) · Nature · doi:10.1038/19539 · Cited by 2,225
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
p63 is a p53 homologue required for limb and epidermal morphogenesis
Mills, A. A., Zheng, B., Wang, X.-J., Vogel, H., Roop, D. R., & Bradley, A. (1999) · Nature · doi:10.1038/19531 · Cited by 1,988
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,813
Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.-C., Valent, A., Minty, A., Chalon, P., Lelias, J.-M., Dumont, X., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80540-1 · Cited by 1,637
Lowe, S. W., Cepero, E., & Evan, G. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,309
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
Post-translational modification of p53 in tumorigenesis
Bode, A. M., & Dong, Z. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1455 · Cited by 1,270
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
Moll, U. M., & Petrenko, O. (2003) · PubMed · Cited by 1,074
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · cited 2×
“There is sufficient evidence in vitro and in vivo to establish an oncogenic role for some human tumorderived p53 mutants (Lang et al., 2004; Olive et al., 2004; Di Agostino et al., 2006).”
BackgroundYang, A., Walker, N., Bronson, R., Kaghad, M., Oosterwegel, M., Bonnin, J., Vagner, C., Bonnet, H., Dikkes, P., Sharpe, A., et al. (2000) · Nature · doi:10.1038/35003607 · Cited by 990
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 869
Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation
Brooks, C. L., & Gu, W. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00003-6 · Cited by 742
Aas, T., Børresen, A.-L., Geisler, S., Smith-Sørensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., & Lønning, P. E. (1996) · Nature Medicine · doi:10.1038/nm0796-811 · Cited by 736
p53 Antibodies in the sera of patients with various types of cancer: a review.
Soussi, T. (2000) · PubMed · Cited by 643
Buck, M. J., & Lieb, J. D. (2004) · Genomics · doi:10.1016/j.ygeno.2003.11.004 · Cited by 608
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.
Moll, U. M., Riou, G., & Levine, A. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.7262 · Cited by 575
Rescuing the function of mutant p53
Bullock, A. N., & Fersht, A. R. (2001) · Nature Reviews Cancer · doi:10.1038/35094077 · Cited by 568
The p53/p63/p73 family of transcription factors: overlapping and distinct functions
Levrero, M., Laurenzi, V. D., Costanzo, A., Sabatini, S., Gong, J., Wang, J. Y. J., & Melino, G. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.10.1661 · Cited by 565
Cloning and functional analysis of human p51, which structurally and functionally resembles p53
Osada, M., Ohba, M., Kawahara, C., Ishioka, C., Kanamaru, R., Katoh, I., Ikawa, Y., Nimura, Y., Nakagawara, A., Obinata, M., et al. (1998) · Nature Medicine · doi:10.1038/nm0798-839 · Cited by 529
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
Marin, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O'Nions, J., Tidy, J. A., James, N., McGregor, J. M., Harwood, C. A., Yulug, I. G., et al. (2000) · Nature Genetics · doi:10.1038/75586 · Cited by 515
p63 and p73: p53 mimics, menaces and more
Yang, A., & McKeon, F. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35043127 · Cited by 483
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464
Blandino, G., Levine, A. J., & Oren, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202314 · Cited by 441
Self-citationDi Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418 · cited 5×
“Recent evidence indicates that mutant p53 is present onto promoter regions together with DNA-binding proteins, acetylases and/ or deacetylases (Di Agostino et al., 2006).”
BackgroundSelf-citationp73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells
Di Como, C. J., Gaiddon, C., & Prives, C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1438 · Cited by 417
Chemosensitivity linked to p73 function
Irwin, M. S., Kondo, K., Marin, M. C., Cheng, L. S., Hahn, W. C., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00078-3 · Cited by 408
Hussain, S. P., & Harris, C. C. (1998) · PubMed · Cited by 407
Strano, S., Monti, O., Pediconi, N., Baccarini, A., Fontemaggi, G., Lapi, E., Mantovani, F., Damalas, A., Citro, G., Sacchi, A., et al. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.008 · Cited by 360
Self-citationDNA Damage-Dependent Acetylation of p73 Dictates the Selective Activation of Apoptotic Target Genes
Costanzo, A., Merlo, P., Pediconi, N., Fulco, M., Sartorelli, V., Cole, P. A., Fontemaggi, G., Fanciulli, M., Schiltz, L., Blandino, G., et al. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00431-8 · Cited by 319
Self-citationp53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding
Midgley, C. A., & Lane, D. P. (1997) · Oncogene · doi:10.1038/sj.onc.1201459 · Cited by 311
The p53MH algorithm and its application in detecting p53-responsive genes
Hoh, J., Jin, S., Parrado, T., Edington, J., Levine, A. J., & Ott, J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132268899 · Cited by 295
Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene.
Purdie, C. A., Harrison, D. J., Peter, A., Dobbie, L., White, S., Howie, S., Salter, D. M., Bird, C., Wyllie, A. H., & Hooper, M. L. (1994) · PubMed · Cited by 290
A novel protein with strong homology to the tumor suppressor p53
Schmale, H., & Bamberger, C. (1997) · Oncogene · doi:10.1038/sj.onc.1201500 · Cited by 283
Regulation of p53 responses by post-translational modifications
Xu, Y. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401182 · Cited by 265
The p53-deficient mouse: a model for basic and applied cancer studies
Donehower, L. A. (1996) · Seminars in Cancer Biology · doi:10.1006/scbi.1996.0035 · Cited by 264
Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73
Strano, S., Munarriz, E., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003360200 · Cited by 240
Self-citationTrink, B., Okami, K., Wu, L., Sriuranpong, V., Jen, J., & Sidransky, D. (1998) · Nature Medicine · doi:10.1038/nm0798-747 · Cited by 238
Gualberto, A., Aldape, K., Kozakiewicz, K., & Tlsty, T. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5166 · Cited by 237
Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activities
Halevy, O., Michalovitz, D., & Oren, M. (1990) · Science · doi:10.1126/science.2218501 · Cited by 234
Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities
Strano, S., Fontemaggi, G., Costanzo, A., Rizzo, M. G., Monti, O., Baccarini, A., Del Sal, G., Levrero, M., Sacchi, A., Oren, M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201405200 · Cited by 226
Self-citationCadwell, C., & Zambetti, G. P. (2001) · Gene · doi:10.1016/s0378-1119(01)00696-5 · Cited by 225
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns, E., Foekens, J. A., van Vossen, R., et al. (2000) · PubMed · Cited by 196
Frazier, M. W., He, X., Wang, J., Gu, Z., Cleveland, J. L., & Zambetti, G. P. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3735 · Cited by 194
Transcriptional Activation of the Human Epidermal Growth Factor Receptor Promoter by Human p53
Ludes-Meyers, J. H., Subler, M. A., Shivakumar, C. V., Munoz, R. M., Jiang, P., Bigger, J. E., Brown, D. R., Deb, S. P., & Deb, S. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.11.6009 · Cited by 182
Kaelin, W. G. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.594 · Cited by 173
Analysis of the gene coding for the murine cellular tumour antigen p53.
Bienz, B., Zakut-Houri, R., Givol, D., & Oren, M. (1984) · The EMBO Journal · doi:10.1002/j.1460-2075.1984.tb02110.x · Cited by 167
Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells
Deb, S., Jackson, C. T., Subler, M. A., & Martin, D. W. (1992) · Journal of Virology · doi:10.1128/jvi.66.10.6164-6170.1992 · Cited by 160
Fontemaggi, G., Kela, I., Amariglio, N., Rechavi, G., Krishnamurthy, J., Strano, S., Sacchi, A., Givol, D., & Blandino, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205573200 · Cited by 155
Self-citationTumor-Derived p53 Mutants Induce NF-κB2 Gene Expression
Scian, M. J., Stagliano, K. E., Anderson, M. A. E., Hassan, S., Bowman, M., Miles, M. F., Deb, S. P., & Deb, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.22.10097-10110.2005 · Cited by 152
Geisler, S. B., Børresen‐Dale, A., Johnsen, H., Aas, T., Geisler, J., Akslen, L. A., Anker, G. B., & Lønning, P. E. (2003) · PubMed · Cited by 151
Covalent and noncovalent modifiers of the p53 protein
Jayaraman, L., & Prives, C. L. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050271 · Cited by 150
ChIP-chip Comes of Age for Genome-wide Functional Analysis
Wu, J., Smith, L. T., Plass, C., & Huang, T. H. ‐. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0276 · Cited by 147
Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma.
Takahashi, H., Ichimiya, S., Nimura, Y., Watanabe, M., Furusato, M., Wakui, S., Yatani, R., Aizawa, S., & Nakagawara, A. (1998) · PubMed · Cited by 142
Mutant p53 protein expression interferes with p53-independent apoptotic pathways
Li, R., Sutphin, P. D., Schwartz, D., Matas, D., Almog, N., Wolkowicz, R., Goldfinger, N., Pei, H., Prokocimer, M., & Rotter, V. (1998) · Oncogene · doi:10.1038/sj.onc.1201867 · Cited by 140
Lin, J., Teresky, A. K., & Levine, A. J. (1995) · PubMed · Cited by 122
A Second p53-Related Protein, p73L, with High Homology to p73
Senoo, M., Seki, N., Ohira, M., Sugano, S., Watanabe, M., Tachibana, M., Tanaka, T., Shinkai, Y., & Kato, H. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9013 · Cited by 120
Margulies, L., & Sehgal, P. B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82442-5 · Cited by 119
Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen.
Oren, M., & Levine, A. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.1.56 · Cited by 119
Modulation of Gene Expression by Tumor-Derived p53 Mutants
Scian, M. J., Stagliano, K. E., Ellis, M. A., Hassan, S., Bowman, M., Miles, M. F., Deb, S. P., & Deb, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1568 · Cited by 117
Mizuarai, S., Yamanaka, K., & Kotani, H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4629 · Cited by 117
A Second p53-Related Protein, p73L, with High Homology to p73
Senoo, M., Seki, N., Ohira, M., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9251 · Cited by 116
Induction of p57 KIP2 expression by p73β
Bálint, É., Phillips, A. C., Козлов, С. В., Stewart, C. L., & Vousden, K. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062491899 · Cited by 97
Mutational analysis of the p73 gene localized at chromosome 1p36.3 in colorectal carcinomas.
Sunahara, M., Ichimiya, S., Nimura, Y., Takada, N., Sakiyama, S., Satō, Y., Todo, S., Adachi, W., Amano, J., & Nakagawara, A. (1998) · International Journal of Oncology · doi:10.3892/ijo.13.2.319 · Cited by 96
Lee, Y. I., Lee, S., Das, G. C., Park, U. S., Park, S. M., & Lee, Y. I. (2000) · Oncogene · doi:10.1038/sj.onc.1203694 · Cited by 94
Mutant p53 proteins bind DNA in a DNA structure-selective mode
hler, T. G. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki252 · Cited by 76
Response of heat shock element within the human HSP70 promoter to mutated p53 genes.
Tsutsumi‐Ishii, Y., Tadokoro, K., Hanaoka, F., & Tsuchida, N. (1995) · PubMed · Cited by 74
Hainaut, P. L., & Wiman, K. G. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6 · Cited by 73
Augustin, M., Bamberger, C., Paul, D., & Schmale, H. (1998) · Mammalian Genome · doi:10.1007/s003359900891 · Cited by 63
Will, K., Warnecke, G., Wiesmüller, L., & Deppert, W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13681 · Cited by 61
Differential regulation of p63 and p73 expression
Waltermann, A., Kartasheva, N. N., & Dobbelstein, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206859 · Cited by 59
Analysis of JNK, Mdm2 and p14ARF contribution to the regulation of mutant p53 stability
Buschmann, T., Minamoto, T., Wagle, N., Fuchs, S. Y., Adler, V., Mai, M., & Ronai, Z. A. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3387 · Cited by 51
Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53
Zalcenstein, A., Weisz, L., Stambolsky, P., Bar, J., Rotter, V., & Oren, M. (2005) · Oncogene · doi:10.1038/sj.onc.1209061 · Cited by 50
Subler, M. A., Martin, D. W., & Deb, S. (1994) · Journal of Virology · doi:10.1128/jvi.68.1.103-110.1994 · Cited by 48
The versatile interactions of p53 with DNA: when flexibility serves specificity
Kim, E., & Deppert, W. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401909 · Cited by 44
Iwanaga, Y., & Jeang, K. (2002) · PubMed · Cited by 43
S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation
Lapi, E., Iovino, A. J., Fontemaggi, G., Soliera, A. R., Iacovelli, S., Sacchi, A., Rechavi, G., Givol, D., Blandino, G., & Strano, S. (2006) · Oncogene · doi:10.1038/sj.onc.1209401 · Cited by 43
Self-citationΔNp73 can modulate the expression of various genes in a p53-independent fashion
Kartasheva, N. N., Lenz-Bauer, C., Hartmann, O., Schäfer, H., Eilers, M., & Dobbelstein, M. (2003) · Oncogene · doi:10.1038/sj.onc.1207138 · Cited by 37
Stiewe, T., Stanelle, J., Theseling, C. C., Pollmeier, B., Beitzinger, M., & Pützer, B. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300357200 · Cited by 37
Comparison of the Effect of Mutant and Wild-Type p53 on Global Gene Expression
O’Farrell, T. J., Ghosh, P., Dobashi, N., Sasaki, C. Y., & Longo, D. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3639 · Cited by 37
p73-Mediated Chemosensitivity: A Preferential Target of Oncogenic Mutant p53
Strano, S., & Blandino, G. (2003) · Cell Cycle · doi:10.4161/cc.2.4.426 · Cited by 37
Self-citationTepper, C. G., Gregg, J. P., Shi, X.-B., Vinall, R. L., Baron, C. A., Ryan, P. E., Desprez, P. Y., Kung, H., & White, R. D. (2005) · The Prostate · doi:10.1002/pros.20308 · Cited by 36
Identification of genomic DNA sequences bound by mutant p53 protein (Gly245→Ser) in vivo
Koga, H., & Deppert, W. (2000) · Oncogene · doi:10.1038/sj.onc.1203745 · Cited by 35
Analysis of p53 Gene Alterations in Cancer: A Critical View
Soussi, T. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_12 · Cited by 14
McKinney, K. M., & Prives, C. L. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_2 · Cited by 10
Joerger, A. C., Friedler, A., & Fersht, A. R. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_17 · Cited by 9
P73, P63 and Mutant P53: Members of Protein Complexs Floating in Cancer Cells
Monti, O., Damalas, A., Strano, S., & Blandino, G. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_10 · Cited by 4
Self-citationCellular senescence and cancer
(1999) · doi:10.1002/(sici)1096-9896(199901)187:1
Cited by
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Inflammation: Gearing the journey to cancer
KUNDU, J., & SURH, Y. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2008.03.002 · Cited by 803
Metadata
- Authors
- Strano, S., Dell'Orso, S., Di Agostino, S., Fontemaggi, G., Sacchi, A., & Blandino, G.
- Venue
- Oncogene
- Published
- 2007-04-02
- Volume
- 26
- Issue
- 15
- Pages
- 2212-2219
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2017449972
- Cited by
- 269
- References
- 98
- FWCI
- 10.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.